Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis
Go back to Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 125.31 -2.31 (1.81%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $127.62 | 52 Week High | $118.49 | |||
| Open | $127.85 | 52 Week Low | $55.00 | |||
| Day High | $128.72 | P/E | N/A | |||
| Day Low | $125.23 | EPS | $-0.56 | |||
| Volume | 3,700,410 | |||||
